Healthcare sentiment
Today’s healthcare market
About the two gauges
Pharma giants follows 15 of the largest drug makers, from momentum (50%), valuation (25%) and insider filings (25%). Biotech follows 23 biotech companies, from strength against the wider biotech index (40%), distance from 52-week highs (35%), and breadth plus new listings (25%).
What drives each gauge
Inside the two gauges
History
How the two gauges have moved
Wide gaps between the lines mean pharma and biotech are telling different stories.
Stocks
Leaders and laggards
Each group over the past 30 days.
Deals
Mergers and acquisitions
Deals signed or completed by drug and biotech companies over the past 90 days, from SEC filings.
Calendar
FDA meetings and decisions
Advisory committee meetings and decision dates coming up.
Common questions
Why two gauges instead of one healthcare score?
Big pharma and biotech are different trades. Big pharma moves on patent expiries, dividends and drugs such as the GLP-1 weight-loss treatments. Smaller biotech moves on trial results, access to funding and FDA decisions. One combined score would hide the difference, and the difference is often the most useful reading.
Why are health insurers not a third gauge?
Insurers such as UnitedHealth and Elevance move on medical costs, Medicare Advantage rates and regulation, not on drug news. They are shown as a separate comparison against the healthcare ETF instead.
What does the M&A section count?
Merger deals signed or completed by US-listed drug, biotech and diagnostics companies over the past 90 days, found by searching the full text of their SEC 8-K filings. Big pharma buying biotech is the clearest sign of how it values the smaller companies.
How often is the data updated?
The gauges and the insurer comparison refresh every weekday after the US close. M&A refreshes daily from SEC EDGAR. FDA meetings come from notices in the Federal Register.
Where does the data come from?
Yahoo Finance for prices and ratios, SEC EDGAR for insider trades (Form 4) and mergers (8-K), Finnhub for the IPO calendar, and the Federal Register for FDA advisory committee meetings. All public and free.
Is this investment advice?
No. It describes what the market has been doing, not what it will do.